SUICIDE PREVENTION

Suicide is a major problem in psychiatry, a drama within the family and act of desperation and unable to see other outlets decided by the person.

Our "free will" is the ability to be free to decide, but how do we know if it is a decision that we would take the same way if we should give some time to reconsider? In most patients who are placed in treatment and have managed to save their lives after a failed attempt to recognize that they did not want to die, but it was the only way out they saw at the time. many depressions treated adequately prevent that risk.

The causes are psychopathological and biological-, personality traits, psychosocial and family. In the literature we have great stories to raise suicide as a vital outlet not devoid of romance, but in some cases biographical, we analyze in this corresponding to major depression or Bipolar , currently and properly treated may give other options and other possibilities of decision.

In the case of adolescent suicide attempts can be impulsive or reprimands which sometimes have been "exposed" in a more or less obvious to the family, but have not given adequate importance. In our practice we find that the patient speaks of self-harm in most cases, parents do not hear it. Psychotherapy family intervention and administration of guidelines can help prevention. 

If we consider that 9 out of 10 cases of suicide have a history of suffering from psychological distress , gives us much to think about why you want to leave to exist. Currently social despair has increased and has led to a greater number of attempts and some fatality, thereforesociety's role on the meaning of life occupies a role that we must not forget .

OZONE THERAPY IN FIBROMYALGIA

Fibromyalgia is a chronic rheumatic disease, according to the Spanish Society of Rheumatology, affecting just over 2% of the population over 20 years, mostly women. People who suffer often complain that hurts them all, since it involves constant pain in muscles, ligaments and tendons, persistent fatigue, sleep disturbances, anxiety and depression as major symptoms.

Some misunderstandings related pathology are those who propagate the disease Fibromyalgia is a completely unknown. However, it is misinformation because in the past 10 years has made considerable progress in the treatment of this disease, and as appropriate for each patient can be carried out to increase exponentially improved their quality of life, should not be accepted never "get used to the pain."

Treatment

Fibromyalgia Treatment should be multidisciplinary and include various physical and pharmacological therapies, recommended based on each patient's presenting symptoms. The application of Ozone with other specific treatments can significantly improve the quality of life of patients. Ozone therapy helps reduce pain and contracture of the muscles through the application of ozone in various ways (general and local).

The Fourth International Congress of the BMES, held in Valencia on 13, 14 and 15 of last June, I presented a paper on Ozone Fibromyalgia applied to the finding that patients treated with ozone therapy and monitored at least five years , they had a much more favorable compared with that group of patients who had not been applied. The study made an impact in the scientific community by the number of treated patients, a sample of over 3,000 in the last 20 years, so this technique is considered an important aid in the management of these patients.

Coronary Disease Comes Slowly To The Basis of Blood Pressure

The People who , the Patients with a  clogged and hardened arteries who already have increase their blood pressure under control may be  benefit from an inductive  additional blood pressure-lowering medication, mainly according to research from the Cleveland Clinic Coordinating Center for Clinical Research (C3Research).

The researchers found that the renin-inhibitor aliskiren tended to slow coronary disease progression and reduced the risk of death, stroke and heart attack in these patients by about 50 percent, compared to placebo, suggesting that patients with prehypertension may benefit from blood pressure lowering drugs.

The results of the AQUARIUS (Aliskerin Quantitative Atherosclerosis Regression Intravascular Ultrasound Study) trial were presented at the European Society of Cardiology Congress 2013 and published simultaneously in the Journal of the American Medical Association.

Aliskiren affects the body's renin-angiotensin-aldosterone system (RAAS), a hormone system that regulates blood pressure and has been shown in prior studies to play an important role in the development of atherosclerosis, or the hardening or clogging of the arteries. As a renin inhibitor, aliskiren partially blocks renin from triggering the RAAS process and is approved to treat hypertension to optimal guidelines of 140/90 mmHg, or the high end of the prehypertensive range